As global regulatory expectations evolve, biotech sponsors face growing pressure to make smarter, earlier decisions about where and how to run their trials.

 

In this episode, Novotech experts Renita Hite (Director of Regulatory Affairs, Drug Development Consulting) and Scott Schliebner (Global Head of Drug Development Consulting) join moderator Meredith Landry to discuss how early-stage sponsors can adapt to shifting FDA initiatives, accelerated global pathways, and increasing demands for regulatory flexibility.

 

They explore:

How new FDA initiatives—like AI-driven reviews, user fee changes, and the National Priority Voucher—are reshaping IND strategy
Why sponsors should design trials with global data packages in mind from day one
Accelerated and early access pathways that can speed startup and market entry
How CROs are evolving to help sponsors prioritize markets and build regulatory flexibility
 

If you’re planning trials for 2025 and beyond, this conversation will help you prepare for what’s next—and position your program for long-term success.

 

About This Episode

This episode is the final installment (4 of 4) in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development.

 

Catch up on earlier episodes:

[Part 1: Navigating Regulatory Changes & Market Dynamics]
[Part 2: Navigating Regulatory & Market Shifts]
[Part 3: Navigating Regulatory Changes & Market Dynamics]

Navigating What’s Next for Global Drug Development: What Sponsors Need to Know

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.